The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

By U. Klein, M. Lia, M. Crespo, R. Siegel, Qiong Shen, Tongwei Mo, A. Ambesi-Impiombato, Andrea Califano, A. Migliazza, G. Bhagat and 1 more. Cancer Cell, 2010

852 citations recorded by the source corpus.

Subfields: Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/50273721ca99f85ac1e1b627ed28bbb0820e49c7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. R. Dalla-Favera
2. Carlo Maria Croce
3. David P. Bartel
4. Phillip A. Sharp
5. Margaret S. Ebert

In Immunology

1. R. Dalla-Favera
2. Carlo Maria Croce
3. Scott W. Lowe

Citations in the corpus

• Metazoan MicroRNAs (2018, background): “…removed Phenotype miR-15/16/195/322/497 (7) miR-15a ~ 16-1 Increased proliferation of B cells; development of lymphoproliferative disorders (Klein et al., 2010); arrested maturation of natural killer cells (Sullivan et al., 2015); increased phagocytosis of macrophages; reduced mortality in…”
• MicroRNA sponges: progress and possibilities. (2010, background): “For the miR-15/16 and miR-144/451 clusters, their respective roles as suppressors of tumor growth and promoters of erythropoiesis are supported by deletion experiments (Klein et al. 2010; Rasmussen et al. 2010).”
• Long Non-Coding RNA in the Pathogenesis of Cancers (2019, background): “In support, deletion of miR-15a/16-1 promotes the proliferation of both human and mouse B cells by accelerating the G0/G1-S phase transition [343].”
• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation (2011, background): “…conceivably the initiating lesion in nearly 50% of CLL cases, followed by the accumula tion of additional alterations during tumor progression, namely del17p13 and del11q22–q23 affecting TP53 and ATM, re spectively (Döhner et al., 2000; Calin et al., 2002; Klein et al., 2010; Zenz et al., 2010b).”
• MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, background): “These include germline transgenic or knockout mice for the following: miR-155, which, if overexpressed in B cell lineage, induces B cell malignancy [113]; miR-21, which leads to lung tumorigenesis if ubiquitously deleted [114]; miR-17-92 and its paralogs, whose overexpression in lymphocytes induces ”
• DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs (2012, background): “Other researchers also support this lncRNA ‘sponge’/ ‘decoy’ function, reducing the regulatory effect of miRNAs on targeted mRNAs (14,15), miRNA precursors (16,17) or host genes for miRNAs (18).”
• The microcosmos of cancer (2012, background): “Ablation of the miR-15a and miR-16-1 cluster, which is often deleted in human chronic lymphocytic leukaemia, predisposes mice to B-cell lymphoproliferative diseas”
• microRNAs in cancer (2013, background): “Several strains of mice lacking or overexpressing cancer-associated miRNAs have been developed and characterized, including the germ-line transgenic or knockout mice of miR155 (39), miR-17/92 and its paralogs (60–62), miR-21 (40), miR-221 (63), the miR-15/16-1 cluster (64), miR-122 (65, 66), and miR”